We assign a fundamental rating of 6 out of 10 to REGN. REGN was compared to 525 industry peers in the Biotechnology industry. REGN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. REGN has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year REGN was profitable.
REGN had a positive operating cash flow in the past year.
In the past 5 years REGN has always been profitable.
Each year in the past 5 years REGN had a positive operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of 11.40%, REGN belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
REGN has a Return On Equity of 14.79%. This is amongst the best in the industry. REGN outperforms 94.67% of its industry peers.
The Return On Invested Capital of REGN (8.69%) is better than 94.48% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for REGN is significantly below the industry average of 18.07%.

		Industry Rank	Sector Rank
ROA	11.4%
ROE	14.79%
ROIC	8.69%

ROA(3y)12.83%

ROA(5y)18.14%

ROE(3y)16.47%

ROE(5y)24.86%

ROIC(3y)12.44%

ROIC(5y)18.14%

1.3 Margins

Looking at the Profit Margin, with a value of 32.13%, REGN belongs to the top of the industry, outperforming 96.57% of the companies in the same industry.
In the last couple of years the Profit Margin of REGN has grown nicely.
REGN's Operating Margin of 27.61% is amongst the best of the industry. REGN outperforms 96.57% of its industry peers.
REGN's Operating Margin has declined in the last couple of years.
REGN has a Gross Margin of 86.28%. This is amongst the best in the industry. REGN outperforms 88.95% of its industry peers.
REGN's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	27.61%
PM (TTM)	32.13%
GM	86.28%

OM growth 3Y-19.71%

OM growth 5Y-2.68%

PM growth 3Y-14.8%

PM growth 5Y2.92%

GM growth 3Y0.28%

GM growth 5Y-0.68%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), REGN is creating some value.
Compared to 1 year ago, REGN has about the same amount of shares outstanding.
Compared to 5 years ago, REGN has less shares outstanding
Compared to 1 year ago, REGN has an improved debt to assets ratio.

2.2 Solvency

REGN has an Altman-Z score of 7.43. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of REGN (7.43) is better than 77.90% of its industry peers.
The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.70, REGN belongs to the top of the industry, outperforming 94.67% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.09, REGN is not doing good in the industry: 61.71% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	0.7
Altman-Z	7.43

ROIC/WACC1

WACC8.69%

2.3 Liquidity

REGN has a Current Ratio of 4.06. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.06, REGN perfoms like the industry average, outperforming 48.76% of the companies in the same industry.
REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.51, REGN is in line with its industry, outperforming 44.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.06
Quick Ratio	3.51

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for REGN have decreased by -0.92% in the last year.
The Earnings Per Share has been growing by 13.12% on average over the past years. This is quite good.
The Revenue has been growing slightly by 2.89% in the past year.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.

EPS 1Y (TTM)-0.92%

EPS 3Y-13.85%

EPS 5Y13.12%

EPS Q2Q%-5.06%

Revenue 1Y (TTM)2.89%

Revenue growth 3Y-4.04%

Revenue growth 5Y12.55%

Sales Q2Q%0.9%

3.2 Future

REGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.62% yearly.
The Revenue is expected to grow by 6.08% on average over the next years.

EPS Next Y-3.81%

EPS Next 2Y0.46%

EPS Next 3Y6.66%

EPS Next 5Y7.62%

Revenue Next Year0.41%

Revenue Next 2Y3.57%

Revenue Next 3Y5.62%

Revenue Next 5Y6.08%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 16.79 indicates a correct valuation of REGN.
Compared to the rest of the industry, the Price/Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.43% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.32. REGN is valued slightly cheaper when compared to this.
REGN is valuated correctly with a Price/Forward Earnings ratio of 16.40.
95.05% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 24.30. REGN is valued slightly cheaper when compared to this.

		Industry Rank	Sector Rank
PE	16.79
Fwd PE	16.4

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaper than 94.86% of the companies in the same industry.
95.43% of the companies in the same industry are more expensive than REGN, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	20.46
EV/EBITDA	15.04

4.3 Compensation for Growth

REGN has an outstanding profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)1.28

EPS Next 2Y0.46%

EPS Next 3Y6.66%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

REGN has a yearly dividend return of 0.47%, which is pretty low.
Compared to an average industry Dividend Yield of 1.18, REGN pays a better dividend. On top of this REGN pays more dividend than 98.29% of the companies listed in the same industry.
With a Dividend Yield of 0.47, REGN pays less dividend than the S&P500 average, which is at 1.86.

		Industry Rank	Sector Rank
Dividend Yield	0.47%

5.2 History

REGN is new to the dividend game and has less than 3 years of track record.

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

DPN/A

EPS Next 2Y0.46%

EPS Next 3Y6.66%

More info and screens

Find the best dividend stocks

Show peers with best dividend

REGENERON PHARMACEUTICALS

NASDAQ:REGN (1/22/2026, 4:04:17 PM)

After market: 755.51 0 (0%)

755.51

+6.18 (+0.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-28 2025-10-28/bmo

Earnings (Next)01-30 2026-01-30/amc

Inst Owners90.13%

Inst Owner Change-0.04%

Ins Owners1.95%

Ins Owner Change3.45%

Market Cap79.40B

Revenue(TTM)14.25B

Net Income(TTM)4.58B

Analysts79.44

Price Target838.03 (10.92%)

Short Float %2.46%

Short Ratio2.51

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0.47%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)35.37%

Min EPS beat(2)20.96%

Max EPS beat(2)49.77%

EPS beat(4)3

Avg EPS beat(4)16.75%

Min EPS beat(4)-8.66%

Max EPS beat(4)49.77%

EPS beat(8)6

Avg EPS beat(8)9.92%

EPS beat(12)10

Avg EPS beat(12)9.47%

EPS beat(16)13

Avg EPS beat(16)8.82%

Revenue beat(2)2

Avg Revenue beat(2)6.19%

Min Revenue beat(2)2.66%

Max Revenue beat(2)9.72%

Revenue beat(4)2

Avg Revenue beat(4)0.54%

Min Revenue beat(4)-9.31%

Max Revenue beat(4)9.72%

Revenue beat(8)4

Avg Revenue beat(8)0.34%

Revenue beat(12)8

Avg Revenue beat(12)1.48%

Revenue beat(16)12

Avg Revenue beat(16)2.04%

PT rev (1m)5.28%

PT rev (3m)12.49%

EPS NQ rev (1m)-0.42%

EPS NQ rev (3m)15.94%

EPS NY rev (1m)-0.1%

EPS NY rev (3m)10.29%

Revenue NQ rev (1m)-0.08%

Revenue NQ rev (3m)4.07%

Revenue NY rev (1m)0.12%

Revenue NY rev (3m)2.47%

Valuation

		Industry Rank	Sector Rank
PE	16.79
Fwd PE	16.4
P/S	5.57
P/FCF	20.46
P/OCF	15.66
P/B	2.56
P/tB	2.68
EV/EBITDA	15.04

EPS(TTM)45.01

EY5.96%

EPS(NY)46.06

Fwd EY6.1%

FCF(TTM)36.93

FCFY4.89%

OCF(TTM)48.25

OCFY6.39%

SpS135.56

BVpS294.56

TBVpS281.42

PEG (NY)N/A

PEG (5Y)1.28

Graham Number546.17

Profitability

		Industry Rank	Sector Rank
ROA	11.4%
ROE	14.79%
ROCE	11.01%
ROIC	8.69%
ROICexc	11.38%
ROICexgc	11.99%
OM	27.61%
PM (TTM)	32.13%
GM	86.28%
FCFM	27.24%

ROA(3y)12.83%

ROA(5y)18.14%

ROE(3y)16.47%

ROE(5y)24.86%

ROIC(3y)12.44%

ROIC(5y)18.14%

ROICexc(3y)18.09%

ROICexc(5y)25.25%

ROICexgc(3y)19.06%

ROICexgc(5y)25.84%

ROCE(3y)15.75%

ROCE(5y)22.96%

ROICexgc growth 3Y-32.64%

ROICexgc growth 5Y-8.74%

ROICexc growth 3Y-33.7%

ROICexc growth 5Y-9.6%

OM growth 3Y-19.71%

OM growth 5Y-2.68%

PM growth 3Y-14.8%

PM growth 5Y2.92%

GM growth 3Y0.28%

GM growth 5Y-0.68%

F-Score5

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	0.7
Debt/EBITDA	0.61
Cap/Depr	226.62%
Cap/Sales	8.35%
Interest Coverage	250
Cash Conversion	113.73%
Profit Quality	84.78%
Current Ratio	4.06
Quick Ratio	3.51
Altman-Z	7.43

F-Score5

WACC8.69%

ROIC/WACC1

Cap/Depr(3y)292.07%

Cap/Depr(5y)265.92%

Cap/Sales(3y)8.85%

Cap/Sales(5y)7.44%

Profit Quality(3y)83.76%

Profit Quality(5y)77.83%

High Growth Momentum

Growth

EPS 1Y (TTM)-0.92%

EPS 3Y-13.85%

EPS 5Y13.12%

EPS Q2Q%-5.06%

EPS Next Y-3.81%

EPS Next 2Y0.46%

EPS Next 3Y6.66%

EPS Next 5Y7.62%

Revenue 1Y (TTM)2.89%

Revenue growth 3Y-4.04%

Revenue growth 5Y12.55%

Sales Q2Q%0.9%

Revenue Next Year0.41%

Revenue Next 2Y3.57%

Revenue Next 3Y5.62%

Revenue Next 5Y6.08%

EBIT growth 1Y-6.18%

EBIT growth 3Y-22.95%

EBIT growth 5Y9.54%

EBIT Next Year-5.21%

EBIT Next 3Y6.05%

EBIT Next 5Y11.85%

FCF growth 1Y-10.97%

FCF growth 3Y-18.47%

FCF growth 5Y12.09%

OCF growth 1Y-2.93%

OCF growth 3Y-14.54%

OCF growth 5Y12.71%

REGENERON PHARMACEUTICALS / REGN FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 6 / 10 to REGN.

What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.

Can you provide the profitability details for REGENERON PHARMACEUTICALS?

REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.

What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?

The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.